Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Blueberries can modify the gut microbiome in older adults with mild depression (opens in a new tab)

medicalxpress.com · 2026-09-29

Short answerEvidenceSource

Short answer

Supported

Supported.

The story matches what the study reports.

  • 5 supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Supported

Every claim holds up. All five claims match what the study reports.

  • 5 supported
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5SupportedA new pilot study found that older, sedentary adults who consumed blueberries daily showed a greater, more consistent reduction in depressive symptoms, along with minor changes in markers of gut microbial enzymes.View evidenceHide evidence

As statedgreater, more consistent reduction; minor changes

Why this verdict

The abstract-level profile reports that the blueberry arm had a larger-magnitude reduction in depressive symptom severity with smaller variability, and that several gut microbial enzyme commission gene abundances changed within the blueberry group. The claim is acceptable because it frames the result as an observed pattern and describes the microbiome changes as minor; however, its lead prominence depends on the accompanying caveat that depression differences were not statistically significant.

1

Study evidence

No changes were detected in fecal bacterial species abundance, MetaCyc pathway abundance, or measured fecal metabolites (SCFAs) over the 3-month intervention.

“randomized, double-blind, parallel-arm, placebo-controlled pilot study”
2

Study evidence

No statistically significant differences in changes in depressive symptoms between the blueberry and placebo groups over 3 months.

“validated questionnaires evaluated depressive symptoms before and after the intervention”
Claim 2 of 5SupportedThe differences in depressive symptoms between the blueberry and placebo groups were not statistically significant.View evidenceHide evidence

Why this verdict

The paper profile explicitly states that there were no statistically significant between-group differences in changes in depressive symptoms.

1

Study evidence

No statistically significant differences in changes in depressive symptoms between the blueberry and placebo groups over 3 months.

“validated questionnaires evaluated depressive symptoms before and after the intervention”
Claim 3 of 5SupportedThe study enrolled sedentary adults 65 and older with mild depressive symptoms in a randomized, double-blind, parallel-arm, placebo-controlled pilot study.View evidenceHide evidence

Why this verdict

The profile describes the study as a randomized, double-blind, parallel-arm, placebo-controlled pilot trial in sedentary adults aged 65 years or older with mild depressive symptoms. Although the claim metadata labels the claim as causal, the text itself is a study-design description rather than an efficacy claim.

1

Study evidence

No changes were detected in fecal bacterial species abundance, MetaCyc pathway abundance, or measured fecal metabolites (SCFAs) over the 3-month intervention.

“randomized, double-blind, parallel-arm, placebo-controlled pilot study”
2

Study evidence

No statistically significant differences in changes in depressive symptoms between the blueberry and placebo groups over 3 months.

“validated questionnaires evaluated depressive symptoms before and after the intervention”
Claim 4 of 5SupportedParticipants consumed 48 grams of blueberry powder per day, or a matched placebo, for three months.View evidenceHide evidence

As stated48 grams per day for three months

Why this verdict

The abstract-level profile states that participants consumed 48 g/day of blueberry powder or placebo for 3 months.

1

Study evidence

No changes were detected in fecal bacterial species abundance, MetaCyc pathway abundance, or measured fecal metabolites (SCFAs) over the 3-month intervention.

“randomized, double-blind, parallel-arm, placebo-controlled pilot study”
2

Study evidence

Fecal short-chain fatty acid (SCFA) measures did not change following 3 months of daily blueberry powder compared with placebo (as reported in the abstract: "Measures of ... metabolites did not change.").

“liquid chromatography/mass spectrometry evaluated gut-derived fecal short chain fatty acids (SCFA)”
Claim 5 of 5SupportedMeasures of gut microbe species abundance, MetaCyc pathways and short-chain fatty acid metabolites did not change, but within the blueberry group there were statistically significant differences in the gene abundance of several enzyme commissions of the gut microbiome, including EC 3.6.3.31 Polyamine Transporting ATPase.View evidenceHide evidence

As statedstatistically significant differences in several enzyme commissions

Why this verdict

The profile reports no detected changes in species abundance, MetaCyc pathway abundance, or fecal metabolites/SCFAs, and reports statistically significant within-blueberry-group changes in several microbial gene-level EC abundances, including EC 3.6.3.31 polyamine-transporting ATPase. The claim appropriately identifies the EC changes as within-group rather than between-group.

1

Study evidence

No changes were detected in fecal bacterial species abundance, MetaCyc pathway abundance, or measured fecal metabolites (SCFAs) over the 3-month intervention.

“randomized, double-blind, parallel-arm, placebo-controlled pilot study”
2

Study evidence

Fecal short-chain fatty acid (SCFA) measures did not change following 3 months of daily blueberry powder compared with placebo (as reported in the abstract: "Measures of ... metabolites did not change.").

“liquid chromatography/mass spectrometry evaluated gut-derived fecal short chain fatty acids (SCFA)”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Pilot study with very small sample size: 18 completers, with Blueberry n=10 and Placebo n=8, limiting power and precision.

    The story presentation says the study was a pilot and preliminary, but the supplied caveats do not indicate the very small completed sample size or the specific power limitation.

    From Randomized, double-blind, parallel-arm, placebo-controlled pilot trial; Randomized double-blind placebo-controlled paral

  • Study completers were predominantly female and white, limiting generalizability.

    This limitation appears in the paper profile but is not included in the story presentation’s claims or caveats.

    From Randomized, double-blind, parallel-arm, placebo-controlled pilot trial; Randomized double-blind placebo-controlled paral

  • Abstract does not provide detailed statistical metrics such as p-values, confidence intervals, effect sizes, or multiple-comparison correction details for the microbiome EC findings.

    The story presentation does not mention the absence of detailed statistical reporting or multiple-testing information, which matters for interpreting the reported EC changes.

    From Randomized, double-blind, parallel-arm, placebo-controlled pilot trial; Randomized double-blind placebo-controlled paral

6 things the story did carry across
  • Randomized, double-blind, parallel-arm, placebo-controlled pilot trial design in sedentary older adults with mild depressive symptoms.
  • Intervention was 48 g/day blueberry powder versus matched placebo for 3 months.
  • Depressive symptom differences between blueberry and placebo groups were not statistically significant, despite a larger-magnitude and less variable reduction in the blueberry arm.
  • No changes were detected in fecal bacterial species abundance, MetaCyc pathway abundance, or fecal metabolites/SCFAs.
  • Several microbial enzyme commission gene abundances changed significantly within the blueberry group, including EC 3.6.3.31; these were within-group findings rather than demonstrated significant between-group effects.
  • The authors characterize the data as preliminary and warranting further research.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDetermine whether 3 months of daily blueberry powder (vs placebo) changes gut microbiome composition and functional potential (species/genes; enzyme commission abundances; MetaCyc pathways) in older sedentary adults with mild depressive symptoms.Randomized, double-blind, parallel-arm, placebo-controlled pilot trialExpand

In plain English

Randomized, double-blind, placebo-controlled 3-month pilot trial in sedentary older adults with mild depressive symptoms testing daily blueberry powder (48 g/day) versus placebo. Shotgun metagenomic sequencing of fecal samples showed no changes in species abundance, MetaCyc pathways, or measured fecal metabolites, but several microbial enzyme commission (EC) gene abundances changed within the blueberry arm (including EC 3.6.3.31, polyamine-transporting ATPase). Findings are preliminary given small sample size and were reported as within-group changes rather than between-group differences.

Key findings

  • No changes were detected in fecal bacterial species abundance, MetaCyc pathway abundance, or measured fecal metabolites (SCFAs) over the 3-month intervention.
  • Within the Blueberry group, several microbial gene-level Enzyme Commission (EC) abundances changed significantly; example cited is EC 3.6.3.31 (polyamine-transporting ATPase), which is involved in polyamine transport and related to GABA production pathways.
“randomized, double-blind, parallel-arm, placebo-controlled pilot study”
What this piece can’t prove
  • Pilot trial with small sample size (18 completers: Blueberry n=10, Placebo n=8), limiting statistical power.
  • Study population described as predominantly female and white, which may limit generalizability.
  • Abstract lacks detailed statistical metrics (p-values, effect sizes, confidence intervals) and methodological specifics on bioinformatic pipelines and multiple comparison correction.

1 further detail could not be confirmed from the summary.

2human in vivoDetermine whether 3 months of daily blueberry powder (vs placebo) changes gut-derived fecal metabolites (SCFAs) in the same participants.Randomized double-blind placebo-controlled parallel-arm pilot trialExpand

In plain English

In this randomized, double-blind, placebo-controlled pilot trial of 48 g/day blueberry powder for 3 months in older, sedentary adults with mild depressive symptoms (n=18), targeted fecal metabolomics by LC/MS found that measures of metabolites, including fecal short-chain fatty acids (SCFAs), did not change over the intervention period as reported in the abstract.

Key findings

  • Fecal short-chain fatty acid (SCFA) measures did not change following 3 months of daily blueberry powder compared with placebo (as reported in the abstract: "Measures of ... metabolites did not change.").
“liquid chromatography/mass spectrometry evaluated gut-derived fecal short chain fatty acids (SCFA)”
What this piece can’t prove
  • Pilot study with small sample size (n = 18 completing the intervention).
  • Abstract does not report numerical results, effect sizes, confidence intervals, or p-values for SCFA outcomes.
  • Study completers were predominantly female and white; limited demographic diversity.

1 further detail could not be confirmed from the summary.

3human in vivoExplore whether 3 months of daily blueberry powder (vs placebo) changes depressive symptom severity (questionnaire-based) in the same participants.Randomized double-blind placebo-controlled parallel-arm pilot trialExpand

In plain English

Randomized, double-blind, placebo-controlled pilot trial in sedentary older adults (≥65 y) with mild depressive symptoms comparing 48 g/day blueberry powder versus placebo for 3 months; depressive symptoms assessed with validated questionnaires at baseline and 3 months. Among 18 completers (placebo n=8, blueberry n=10), there were no statistically significant between-group differences in change in depressive symptoms, though the blueberry group showed a larger-magnitude reduction with less variability.

Key findings

  • No statistically significant differences in changes in depressive symptoms between the blueberry and placebo groups over 3 months.
  • Authors noted that the magnitude of reduction in depressive symptom severity appeared greater, with smaller variability, in the Blueberry Group compared with placebo.
“validated questionnaires evaluated depressive symptoms before and after the intervention”
What this piece can’t prove
  • Small pilot sample (18 completers) limits statistical power and precision.
  • Abstract lacks details on which validated depressive symptom questionnaires were used and on statistical estimates (effect sizes, confidence intervals, p-values).
  • Participants who completed the study were predominantly female and white, limiting generalizability.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 23 candidate papers

And 17 more candidates considered.